Finota^®

Everolimus

Product Information

Proprietary Name: Finota®
Generic Name: Everolimus
Dosage Form: Tablet
Strengths: 5 mg, 10 mg
Indications: Hormone Receptor-Positive HER2-Negative Breast Cancer, Neuroendocrine Tumors (NET), Renal Cell Carcinoma (RCC), Tuberous Sclerosis Complex (TSC).

Download Leaflet

Oncology

Finota®

Everolimus is indicated for the treatment of hormone receptor-positive HER2-negative breast cancer, neuroendocrine tumors (NET), renal cell carcinoma (RCC), and tuberous sclerosis complex (TSC).

Apply for a Job Position

Curious about job opportunities?

Signup for a job

Finota®

Product Information

Finota®

Apply for a Job Position

Products

Support

Company

Follow Us

Finota^®